Recommended
Recommended
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharm Ord (NQ: AUPH )

8.340 +0.820 (+10.90%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aurinia Pharm Ord

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Tesla, Nike, Sigilon Therapeutics Among Top Trending Stocks Today
Via Benzinga
Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy
From Aurinia Pharmaceuticals Inc.
Via Business Wire
LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Earnings Perspective: Return On Capital Employed
Via Benzinga
Aurinia Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Why Aurinia Pharmaceuticals Stock Is Glowing Green Today
Investors appear to be cheering another patent win by the company. 
Via The Motley Fool
Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces 2023 Annual General Meeting Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tesla, AMD, Ford, Starbucks, Aurinia Pharma: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual General Meeting
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Glass Lewis Recommends Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual Meeting
From Aurinia
Via Business Wire
3 Biotechs That Might Get Bought Out in 2023
Biotech is expected to be a hotbed of mergers and acquisitions this year. 
Via The Motley Fool
Toni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Second Quarter Outlook For Biotech Stocks
Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. 
Via Talk Markets
Is Aurinia Pharmaceuticals Up for Grabs? Shareholder Suggests a Quick Sale for a Bigger Payday
Via Benzinga
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office
From Aurinia Pharmaceuticals Inc.
Via Business Wire
3 Stocks That Already Doubled in 2023 and Could Keep Climbing
The gains these stocks notched in the first few months of the year could be the beginning of a much longer bull run. 
Via The Motley Fool
What's Going On With Aurinia Pharmaceuticals Stock Wednesday?
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading higher Wednesday after the company announced "promising results" from its AURORA 
Via Benzinga
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
What's Going On With Aurinia Pharmaceuticals Stock Today?
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) shares are trading higher after the company reported better-than-expected fourth-quarter EPS and sales fig 
Via Benzinga
Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates
From Aurinia Pharmaceuticals Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.